Xeris Biopharma Holdings annual shares outstanding
2021
2022
2023
2024
2025
Xeris Biopharma Holdings Shares Outstanding History (XERS)
Xeris Biopharma Holdings reported 166.2M shares outstanding at the end of fiscal 2025.
View full Xeris Biopharma Holdings company overviewXeris Biopharma Holdings annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 166.2M | 16.8M | +11.23% |
| 2024 | 2024-12-31 | 149.4M | 11.3M | +8.18% |
| 2023 | 2023-12-31 | 138.1M | 1.9M | +1.36% |
| 2022 | 2022-12-31 | 136.3M | 11.4M | +9.13% |
| 2021 | 2021-12-31 | 124.9M | — | — |
Xeris Biopharma Holdings quarterly shares outstanding
Q3.21
Q4.21
Q3.22
Q4.22
Q3.23
Q4.23
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 173.6M | 12.4M | +7.67% |
| Q1 2026 | 2026-03-31 | 172.6M | 16.5M | +10.60% |
| Q4 2025 | 2025-12-31 | 166.2M | 16.8M | +11.23% |
| Q3 2025 | 2025-09-30 | 165.5M | 16.5M | +11.09% |
| Q2 2025 | 2025-06-30 | 161.2M | 12.3M | +8.25% |
| Q1 2025 | 2025-03-31 | 156.0M | 17.9M | +12.95% |
| Q4 2024 | 2024-12-31 | 149.4M | 11.4M | +8.23% |
| Q3 2024 | 2024-09-30 | 149.0M | 12.7M | +9.34% |
| Q2 2024 | 2024-06-30 | 148.9M | 13.0M | +9.54% |
| Q4 2023 | 2023-12-31 | 138.1M | 13.3M | +10.62% |
| Q3 2023 | 2023-09-30 | 138.1M | 71.6M | +107.63% |
| Q4 2022 | 2022-12-31 | 136.3M | — | — |
| Q3 2022 | 2022-09-30 | 136.0M | — | — |
| Q4 2021 | 2021-12-31 | 124.9M | — | — |
| Q3 2021 | 2021-09-30 | 66.5M | — | — |
Xeris Biopharma Holdings shares outstanding trends
Across the available reported history, Xeris Biopharma Holdings's shares outstanding moved from 149.4M to 166.2M, a change of 16.8M. The latest reported quarter, Q2 2026, shows 173.6M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xeris Biopharma Holdings filings at SEC.gov ↗